PCRX · Insider Trading
Pacira BioSciences, Inc. Common Stock
Every open-market purchase and sale reported by PCRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-03 | Shawn Cross | Chief Financial Officer | F | −9,540 | −$347.16K |
| 2026-10-09 | Lauren Riker | Senior Vice President, Finance | MIXED | — | −$23.82K |
| 2026-08-18 | Jonathan Slonin | Chief Medical Officer | Sell | −3,040 | −$70.62K |
| 2026-06-12 | Lauren Riker | Senior Vice President, Finance | Sell | −6,115 | −$143.70K |
| 2026-06-12 | Marcelo Bigal | Director | A | +6,405 | — |
| 2026-06-12 | Michael J. Yang | Director | A | +6,405 | — |
| 2026-06-12 | Mark Froimson | Director | A | +6,405 | — |
| 2026-06-12 | Alethia Young | Director | A | +6,405 | — |
| 2026-06-12 | Laura Brege | Director | A | +6,405 | — |
| 2026-06-12 | Samit Hirawat | Director | A | +6,405 | — |
| 2026-06-12 | Christopher Christie | Director | A | +6,405 | — |
| 2026-06-12 | Thomas G Wiggans | Director | A | +32,675 deriv. | — |
| 2026-06-05 | Jonathan Slonin | Chief Medical Officer | F | −4,728 | −$105.53K |
| 2026-06-05 | Lauren Riker | Senior Vice President, Finance | F | −3,187 | −$71.13K |
| 2026-06-05 | Kristen Williams | Chief Administrative Officer | MIXED | −18,787 | −$418.81K |
| 2026-04-24 | Shawn Cross | Chief Financial Officer | MIXED | — | −$112.72K |
| 2026-04-22 | Shawn Cross | Chief Financial Officer | MIXED | — | −$104.23K |
| 2026-03-19 | Mark A. Kronenfeld | Director | A | +6,163 | — |
| 2026-03-19 | Jonathan Slonin | Chief Medical Officer | Sell | −3,261 | −$74.42K |
| 2026-03-19 | Mark Froimson | Director | Sell | −500 | −$10.90K |
| 2026-02-13 | Frank D. Lee | Chief Executive Officer | A | +261,818 | — |
| 2026-02-13 | Lauren Riker | Senior Vice President, Finance | A | +19,273 | — |
| 2026-02-13 | Kristen Williams | Chief Administrative Officer | A | +54,546 | — |
| 2026-02-13 | Jonathan Slonin | Chief Medical Officer | A | +54,546 | — |
| 2026-02-13 | Shawn Cross | Chief Financial Officer | A | +49,091 | — |
| 2026-02-13 | Brendan Teehan | Chief Commercial Officer | A | +51,714 | — |
| 2026-02-03 | Kristen Williams | Chief Administrative Officer | MIXED | −30,271 | −$621.63K |
| 2026-02-03 | Frank D. Lee | Chief Executive Officer | F | −41,488 | −$852.16K |
| 2026-02-03 | Jonathan Slonin | Chief Medical Officer | F | −6,168 | −$126.69K |
| 2026-02-03 | Brendan Teehan | Chief Commercial Officer | F | −5,182 | −$106.44K |
| 2026-02-03 | Lauren Riker | Senior Vice President, Finance | MIXED | −6,751 | −$139.75K |
| 2026-01-29 | Samit Hirawat | Director | A | +39,291 deriv. | — |
| 2026-01-06 | Frank D. Lee | Chief Executive Officer | F | −9,272 | −$226.79K |
| 2026-01-06 | Jonathan Slonin | Chief Medical Officer | F | −381 | −$9.32K |
| 2026-01-06 | Lauren Riker | Senior Vice President, Finance | MIXED | −1,575 | −$38.21K |
| 2026-01-06 | Brendan Teehan | Chief Commercial Officer | A | +402 | +$4.33K |
| 2025-12-11 | Shawn Cross | Chief Financial Officer | MIXED | — | −$215.50K |
| 2025-11-19 | Jonathan Slonin | Chief Medical Officer | Sell | −3,960 | −$95.40K |
| 2025-11-13 | Shawn Cross | Chief Financial Officer | Sell | −12,060 | −$266.41K |
| 2025-11-03 | Shawn Cross | Chief Financial Officer | F | −6,690 | −$143.03K |
| 2025-09-08 | Abraham Ceesay | Director | Sell | −2,354 | −$64.01K |
| 2025-08-11 | Marcelo Bigal | Director | Sell | −4,912 | −$116.27K |
| 2025-08-04 | Jonathan Slonin | Chief Medical Officer | F | −315 | −$6.95K |
| 2025-06-13 | Michael J. Yang | Director | A | +6,163 | — |
| 2025-06-13 | Marcelo Bigal | Director | A | +6,163 | — |
| 2025-06-13 | Christopher Christie | Director | A | +6,163 | — |
| 2025-06-13 | Mark A. Kronenfeld | Director | A | +9,999 | — |
| 2025-06-13 | Alethia Young | Director | A | +6,163 | — |
| 2025-06-13 | Laura Brege | Director | A | +6,163 | — |
| 2025-06-13 | Mark Froimson | Director | A | +6,163 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Frank D. Lee | Chief Executive Officer | 660,830 | $24.09M |
| Jonathan Slonin | Chief Medical Officer | 216,383 | $7.89M |
| Kristen Williams | Chief Administrative Officer | 167,062 | $6.09M |
| Daryl Gaugler | Chief Operating Officer | 115,443 | $4.21M |
| Brendan Teehan | Chief Commercial Officer | 100,934 | $3.68M |
| Shawn Cross | Chief Financial Officer | 95,801 | $3.49M |
| Lauren Riker | Senior Vice President, Finance | 62,284 | $2.27M |
| Mark A. Kronenfeld | Director | 31,065 | $1.13M |
| Laura Brege | Director | 30,120 | $1.10M |
| Mark Froimson | Director | 26,541 | $967.68K |
| Christopher Christie | Director | 23,059 | $840.73K |
| Michael J. Yang | Director | 19,798 | $721.84K |
| Alethia Young | Director | 17,798 | $648.92K |
| Marcelo Bigal | Director | 17,798 | $648.92K |
| Abraham Ceesay | Director | 9,039 | $329.56K |
| Samit Hirawat | Director | 6,405 | $233.53K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PCRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.